PRINCETON, N.J. (April 10, 2020) – Otsuka announces today the extension of its patient support programs, Otsuka Patient Support and Otsuka Patient Assistance Foundation, to provide “no-cost” access to its branded portfolio of prescription medicines for patients in the U.S. who have lost a job or health insurance coverage due to the COVID-19 (coronavirus) pandemic.
For more information, please visit otsukapatientsupport.com or call 1-855-242-7787 (M-F, 8am-8pm EDT).
“Unfortunately, the COVID-19 virus has already taken an enormous toll on too many families and our hearts go out to those who have been affected by this global pandemic,” said Kabir Nath, president & CEO, Otsuka North America Pharmaceutical Business. “In the midst of this crisis, our purpose at Otsuka becomes more meaningful in helping people worry less about maintaining access to the critical treatments they rely on. We feel privileged to be able to provide cost-free Otsuka medicine to those impacted most by this situation.
About Otsuka Pharmaceutical
Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.
In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, renal and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.
Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 1,700 employees in the U.S. develop and commercialize medicines in the areas of mental health, nephrology and cardiology, using cutting-edge technology to address unmet healthcare needs. Otsuka’s most recently approved product in the U.S. is the first-ever treatment for autosomal dominant polycystic kidney disease, a genetic disorder in which fluid-filled cysts develop in the kidneys over time, often leading to kidney failure.
OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Company, Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 11.7 billion in 2018.
All Otsuka stories start by taking the road less travelled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at www.otsuka.co.jp/en/.